

Semaglutide Therapy for Alcohol Reduction (STAR)

NCT06015893

Status	RECRUITING
Phase	Phase 2
Sponsor	National Institute on Drug Abuse (NIDA)
Enrollment	52 participants

Key Eligibility Criteria

Inclusion (11)

- This study will enroll adult individuals with a current diagnosis of AUD. Participants will be recruited without any preference to sex, race, religion, or other social variables, but sociodemographic data will be collected for sample characterization and potential use in the analyses. Since self-reported psychological measures that have been validated in English constitute major part of the study assessments, participants need to be able to speak, read, write, and understand English to be in the study.
- The information needed to assess eligibility will be collected under an IRB-approved NIDA IRP
- screening protocol, led by the Office of the Clinical Director (OCD) at the NIDA IRP to assess
- potential research participants' eligibility for entering clinical protocols. Additional details can be found in the NIDA screening protocol documents. Furthermore, NIH medical records (from other NIH clinical protocols) and outside medical records may also be used, if available, to determine whether participants fulfill the eligibility criteria.
- To be eligible for this study, an individual must meet all of the following criteria:
... and 6 more (see full listing online)

Exclusion (22)

- An individual who meets any of the following criteria will be excluded from enrolling in this study:
- BMI $< 23 \text{ kg/m}^2$ or BMI $\geq 50 \text{ kg/m}^2$
- Evidence of malnutrition as determined by the Nutrition Risk Screening 2002 (NRS-2002)
- Most recent blood tests: creatinine $\geq 2 \text{ mg/dL}$, eGFR $< 45 \text{ mL/min/1.73 m}^2$, triglycerides $> 500 \text{ mg/dl}$, ALP $> 4x$ the upper limit of normal, clinically abnormal lipase levels per study clinician
- Present diagnosis of diabetes mellitus or blood hemoglobin A1c (HbA1c) $\geq 6.5 \%$
... and 17 more (see full listing online)

Locations (1 total)

National Institute on Drug Abuse, Baltimore, Maryland, United States

<https://clinicaltrials.gov/study/NCT06015893>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.